Effects of rosuvastatin on IL-6, GMP-140, BNP and cardiac function on the treatment of the elderly patients with acute coronary syndrome
Objective To investigate and analyze the effects of rosuvastatin on IL-6, GMP-140, BNP and cardiac function on the treatment of the elderly patients with acute coronary syndrome. Methods 66 elderly patients with acute coronary syndromes were selected from May 2015 to April 2017 in Tianjin Nankai Hospital. were randomly divided into control group and experimental group, 33 cases in each group. The control group were received routine oxygen inhalation and low molecular weight heparin, at this basis, and the experimental group were treated with rosuvastatin, 10 mg/d. All the patients were treated for 8 months. The heart function, interleukin -6, GMP-140, BNP and other clinical indexes before and after treatment in the two groups were compared and analyzed. Results After treatment, the level of LVEF in the experimental group was (60.12 ± 7.83)%, which was significantly higher than that in the control group (52.32 ± 6.67)%, the difference had statistically significant (P<0.05). The level of interleukin -6 in the control group was (32.20 ±4.23) ng/L, which was significantly higher than that in the experimental group (14.90 ± 4.23) ng/L, the difference had statistically significant (P<0.05). In addition, the levels of BNP and GMP-140 in the experimental group were (98.20 ± 37.65) ng/L, and (23.21 ± 5.43) μg / L, which were significantly lower than that in the control group, the difference had statistically significant (P<0.05). Conclusion Rosuvastatin was used in elderly patients with acute coronary syndrome, which can significantly alleviate the inflammatory reaction in the body, improve heart function, reduce serum GMP-140, BNP and interleukin -6 level.